Lupus erythematosus - Lupus Eritematoso
☆ En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
Aparece como un eritema ligeramente violáceo.
La erupción en forma de mariposa que suele aparecer en la cara.
References
Identificar y clasificar cutaneous lupus erythematosus (CLE) plantea desafíos diagnósticos, distinguiéndolo de systemic lupus erythematosus con afectación cutánea. Estudios recientes arrojan luz sobre los factores genéticos, ambientales e inmunológicos que subyacen al CLE. Específicamente, la inducción de fármacos se ha convertido en uno de los desencadenantes más importantes del CLE. El tratamiento implica terapias tópicas y sistémicas, incluidos productos biológicos prometedores como belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 , con eficacia demostrada en ensayos clínicos.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) cubre varios problemas de la piel, algunos de los cuales podrían estar relacionados con problemas de salud más amplios. Se clasifica en diferentes tipos, como acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE comprende discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus es un grupo de enfermedades autoinmunes que pueden afectar diferentes partes del cuerpo. Algunos tipos, como systemic lupus erythematosus (SLE) , afectan a múltiples órganos, mientras que otros, como cutaneous lupus erythematosus (CLE) , afectan principalmente a la piel. Clasificamos diferentes tipos de CLE según una combinación de signos clínicos, examen de tejidos y análisis de sangre, pero existe mucha variación entre individuos. Los problemas de la piel a menudo se desarrollan debido a factores como la exposición a la luz solar, el tabaquismo o ciertos medicamentos.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
La causa del lupus eritematoso (lupus erythematosus) no está clara. Entre los gemelos idénticos, si uno está afectado hay un 24% de posibilidades de que el otro también lo esté. También se cree que las hormonas sexuales femeninas, la luz solar, el tabaquismo, la deficiencia de vitamina D y ciertas infecciones aumentan el riesgo.
Los tratamientos pueden incluir AINE, corticosteroides, inmunosupresores, hidroxicloroquina y metotrexato. Aunque los corticosteroides son eficaces, el uso prolongado produce efectos secundarios.